Not actually the question since countries with modern healthcare systems provide all types of insulin at an average cost per unit that is roughly 1/10th to 1/20th the cost in the United States (cheap vs. expensive is an over simplification).

No, it is the question because countries with public health systems often don’t pay for the latest generation of drugs, since they don’t feel the extra cost is worth the benefit.

My comment answered that "countries with public health systems" actually do "pay" for the "latest generation insulin" (i.e. the price for the "latest generation insulin" is still a tiny fraction the cost in the United States).

Just repeating the question, when I gave you the answer, isn't very productive.

It's still the wrong question to ask.

We should ask what are the outcomes that these systems produce, not how new the drugs are.

A cutting-edge healthcare system plagued by inequality and extreme costs can produce worse results than a more efficient healthcare system which is not as high-tech.

Well all the diabetics in this discussion are claiming they can’t do without the latest generation insulin.

But yes, I agree. Sometimes the juice isn’t worth the squeeze.